CAMP4 Therapeutics Corporation Finance Lease, Liability, Undiscounted Excess Amount
CAMP4 Therapeutics Corporation (CAMP) had Finance Lease, Liability, Undiscounted Excess Amount of $6.00 thousand as of 2025-09-30, per its 10-Q filed 2025-11-06.
Financial Statements › Notes › Leases
us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount · last filed 2025-11-06
- 2025-09-30: Finance Lease, Liability, Undiscounted Excess Amount $6.00K.
- 2025-06-30: Finance Lease, Liability, Undiscounted Excess Amount $8.00K.
- 2025-03-31: Finance Lease, Liability, Undiscounted Excess Amount $22.00K.
- 2024-12-31: Finance Lease, Liability, Undiscounted Excess Amount $12.00K.
| Period end | Finance Lease, Liability, Undiscounted Excess Amount |
|---|---|
| 2025-09-30 | $6.00K 10-Q · filed 2025-11-06 |
| 2025-06-30 | $8.00K 10-Q · filed 2025-08-14 |
| 2025-03-31 | $22.00K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $12.00K 10-K · filed 2025-03-27 |
| 2024-09-30 | $17.00K 10-Q · filed 2024-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |